Elbert Glover

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Elbert D. Glover is a researcher and writer in the field of tobacco addiction and smoking cessation. He is Professor of Public Health and Chair of the Department of Behavioral and Community Health at the University of Maryland at College Park School of Public Health.

Biography[edit]

Glover was born at the Kingsville Naval Base in Kingsville, Texas in 1945, where his father was stationed in the US Navy. He is the oldest of 8 children. Upon graduation from Roy Miller High School in Corpus Christi, Texas in 1963, he attended Texas Tech University on a football scholarship and graduaed in 1969. In 1972, he received a master's degree from Texas A&I University and in 1977 a PhD from Texas Woman's University, all in Health Education.[citation needed]

He has served as a professor at Texas A&M University, University of Kansas, Texas Christian University, Texas Woman's University, Texas College of Osteopathic Medicine, Oklahoma State University, East Carolina University,[1] Penn State University, West Virginia University School of Medicine,[2] and the University of Maryland at College Park School of Public Health. At the University of Maryland, he served as chair of the Department of Behavioral and Community Health, and founding director of the Center for Health Behavior Research.[citation needed]

Research[edit]

Glover's primary research interest is the development of cessation aids for people interested in stopping the use of tobacco. As of 1987, he was study a recent in the increased use of smokeless tobacco.[3] He has conducted clinical trials with the use of many delivery forms of nicotine available on the US and European markets, including gum, transdermal patches, oral nicotine inhalers, nasal spray, and sublingual tablets. Glover also conducted trials with bupropion (Zyban, a monocyclic antidepressant) and varenicline (Chantix, a nicotine receptor and partial agonist) which resulted in both being approved for use in the US. In addition, he has studied the use of lobeline as a nicotine blocker,[4] and various psychoactive substances including anti-depressants and anti-anxiety agents. He has also investigated rimonabant (an endocabinnoid), varenicline (a nicotine receptor partial agonist)[5] and 3′AmNic-rEPA (a nicotine conjugate vaccine).[6]

He has received research grants from the government U.S. Department of Education, Centers for Disease Control, National Cancer Institute, National Institute of Drug Abuse, and National Institutes of Health. He has also received grants from the manufacturers of the smoking cessations aids or pharmaceuticals ALZ Corporation, AstraZeneca, Bristol-Myers Squibb, Burroughs Wellcome, Ciba-Geigy, DrugAbuse Sciences, DynaGen, Eli Lilly, Glaxo Wellcome, Healthcare Products Development, KABI Pharmacials, Knoll Pharmaceuticals, LEO Pharmaceuticals, Marion Merrell Dow, NABI Pharmaceuticals, Pharmacia, Pfizer, Sano, Sanofi-Synthelabo, SmithKline Beecham, Parke-Davis, Takeda, and Upjohn.[7]

Professional accomplishments[edit]

His research has resulted in his authoring or co-authoring more than 200 professional publications and receiving approximately $45 millon dollars in grant funding primarily in the area of tobacco. He has delivered over 550 invited medical grand rounds/workshops on the subject to physicians and also presented 335 national and international professional presentations to various medical and health professional organizations.

Glover is publisher and editor of the American Journal of Health Behavior, Health Behavior and Policy Review and Tobacco Regulatory Science. He is the founder and first president of the American Academy of Health Behavior (AAHB),[8] and in 2003 received their Distinguished Scholar Award. In 2005 he received the Alliance Scholar for AAHPERD and in 2008 received the coveted American Academy of Health Behavior Research Laureate Medallion for his contribution to health behavior research. As the founder of the American Academy of Health Behavior was awarded the Lifetime Achievement Award by the Academy. He is a fellow of the American Academy of Health Behavior, the American School Health Association & the Royal Institute of Public Health.

Public work[edit]

Glover has appeared on many television programs, including Dateline, 20/20, The Charlie Rose Show, Good Morning America, PM Magazine, Health Talk America, MD-TV, CBS Morning News, Peter Jennings News World Report, and NBC Evening News. His research has been featured in numerous popular publications such as Ladies Home Journal, Newsweek, Readers Digest, Seventeen, Time, and USA Today.[citation needed]

He serves in various capacities primarily as reviewer for 20 key health academic journals and/or publications among these are the American Journal of Public Health, Addictive Behaviors, NCI Journal, Journal Clinical Advances in Smoking Cessation, Physician and Sportsmedicine, Medical Self-Care, Public Health Reports, American Journal of Health Education, Journal of School Health, Journal of Family Practice, Journal of Alcohol and Drug Education, Advances in Dental Research, Mayo Clinic Proceedings, Southern Medical Journal, Nicotine and Tobacco Research, Drug Discovery Today, and the Journal of the American Medical Association.[citation needed]

References[edit]

  1. ^ Brown, Vicki; Brown, Vicki (1985-12-04). "Lawsuit Says Snuff Killed Teen-Ager". The Washington Post. ISSN 0190-8286. Retrieved 2017-08-01. 
  2. ^ Blumenfeld, Laura (1992-04-02). "Focus". The Washington Post. ISSN 0190-8286. Retrieved 2017-08-01. 
  3. ^ Boul, David (1987-08-23). "WHAT'S NEW IN TOBACCO; His and Hers Chewing and Dipping". The New York Times. ISSN 0362-4331. Retrieved 2017-08-01. 
  4. ^ Glover, Elbert D.; Rath, Jessica M.; Sharma, Eva; Glover, Penny N.; Laflin, Molly; Tonnesen, Philip; Repsher, Lawrence; Quiring, John (2010-01-01). "A Multicenter Phase 3 Trial of Lobeline Sulfate for Smoking Cessation". American Journal of Health Behavior. 34 (1): 101–109. doi:10.5993/AJHB.34.1.12. 
  5. ^ Glover, Elbert D.; Rath, Jessica M. (2007-08-01). "Varenicline: progress in smoking cessation treatment". Expert Opinion on Pharmacotherapy. 8 (11): 1757–1767. doi:10.1517/14656566.8.11.1757. ISSN 1465-6566. 
  6. ^ Hatsukami, Dk; Jorenby, De; Gonzales, D; Rigotti, Na; Glover, Ed; Oncken, Ca; Tashkin, Dp; Reus, Vi; Akhavain, Rc (2011-03-01). "Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic". Clinical Pharmacology & Therapeutics. 89 (3): 392–399. doi:10.1038/clpt.2010.317. ISSN 1532-6535. PMC 4106715Freely accessible. 
  7. ^ [1]
  8. ^ McDermott, Robert J.; Glover, Elbert D. (September 2010). "Formation and early history of the American Academy of Health Behavior" (PDF). American Journal of Health Behavior. 34 (5): 563–572. ISSN 1945-7359. PMID 20524886. 
  • Black, R., and Laflin, M. (2003). Viewpoint: Conversation with Elbert D. Glover, PhD, FASHA, FRIPH, FAAHB. American Journal of Health Behavior, 27(6)
  • "Elbert D. Glover . . . Smokeless tobacco researcher," Pieces of Eight, May 1, 1987. [2] ]
  • Nuzzo, R. (2006). "For smokers: A shot at quitting." Los Angeles Times. [3]
  • "Quitters get a shot in the arm" Daily Record (Baltimore, Maryland), July, 2006. [4]

External links[edit]